Microbiota-modulating interventions are an emerging strategy to promote gastrointestinal homeostasis. Yet, their use in the detection, prevention, and treatment of acute infections remains underexplored. We report the basis of a probiotic-based strategy to promote colonization resistance and point-of-need diagnosis of cholera, an acute diarrheal disease caused by the pathogen Vibrio cholerae. Oral administration of Lactococcus lactis, a common dietary fermentative bacterium, reduced intestinal V. cholerae burden and improved survival in infected infant mice through the production of lactic acid. Furthermore, we engineered an L. lactis strain that specifically detects quorum-sensing signals of V. cholerae in the gut and triggers expression of an enzymatic reporter that is readily detected in fecal samples. We postulate that preventive dietary interventions with fermented foods containing natural and engineered L. lactis strains may hinder cholera progression and improve disease surveillance in populations at risk of cholera outbreaks.
INTRODUCTION
Cholera is a life-threatening gastrointestinal infection that principally affects populations where basic sanitation and healthcare are insufficient (1) . Severe dehydration from cholera can lead to death within hours if treatment is not provided promptly. Strengthening surveillance and early identification of cholera cases are top priorities of the World Health Organization for the prevention of cholera outbreaks. Therefore, implementation of cost-effective measures that prevent disease progression-from initial infection to active disease and dissemination-is urgently needed. Microbiota interventions have been used to treat or alleviate a variety of gastrointestinal disorders (2, 3) . In the case of cholera, it has been demonstrated that natural members of the human microbiome can reduce colonization of Vibrio cholerae in gnotobiotic mice through interference of the pathogen's quorum-sensing signaling (4) . Furthermore, engineered probiotics have been used to interfere with bacterial communication to suppress virulence (5), or to compete with intestinal receptor binding to the cholera toxins (6) . Laboratory strains of Escherichia coli have also been engineered for the detection of V. cholerae signals under culture conditions (7) . However, the demonstration of the in vivo functionality of engineered V. cholerae detection systems in safely consumed, gut-relevant bacteria is lacking.
Food-associated bacteria play a central role in the function and health of the gastrointestinal tract (8) . High doses of ingested, live bacteria can create a microbiota shift that allows transient modulation of the human intestinal microenvironment (8) , a phenomenon that can be leveraged to reduce pathogen colonization (9) and enable in situ diagnosis at an early stage of infection. We hypothesized that dietary-associated bacteria with natural infection-antagonizing properties could be identified, applied, and further enabled with engineered diagnostic functions to ameliorate the impact of cholera and facilitate disease surveillance in populations at risk of infection. mock-treated mice at 26 hours after infection (Fig. 2C) . We found that the V. cholerae load correlates with the infection outcome (Fig. 2C) . Regardless of the probiotic intervention, mice that died from cholera have V. cholerae developed to 10 9 CFU in the gut; the ones that survived until the end of study had lower than 10 8 CFU. This correlation between reduced V. cholerae burden and mouse survival includes mice that were not fed L. lactis (Fig. 2C) , further suggesting that L. lactis assists in mouse survival through reduced V. cholerae colonization. These findings indicate that a regular feeding regimen of L. lactis can prevent the aggressive development of cholera by limiting the bacterial burden to nonlethal concentrations in infant mice.
To further investigate the involvement of L. lactis lactic acid production in the reduction of V. cholerae burden in vivo, we measured the intestinal lactate levels during V. cholerae mouse infections. At 26 hours after infection, mice that were fed L. lactis exhibited increased levels of lactate in the gut compared to mice that had been mock inoculated (Fig. 2D) . When the lactate dehydrogenase mutant strain of L. lactis was used, the protective effect against V. cholerae infection disappeared (Fig. 2E) . Abolishing lactate dehydrogenase function reroutes carbon flux toward mixed acid fermentation pathways and results in a slower growth rate ( fig. S6 ), an effect that might also contribute to its reduced protective effect in vivo. Genetic complementation with plasmid-encoded ldh restored both the strain's growth rate and acidification capabilities, and consequently its protective function in vivo ( Fig. 2E and fig. S6 ). As expected, when heat-inactivated cells were used instead of live L. lactis, the survival rate of the treated mice was similar to the mock-fed group, indicating that metabolically active L. lactis are needed for effective protection (Fig. 2F) . These findings suggest that in situ production of lactic acid by metabolically active bacteria inhibits V. cholerae colonization and is essential for L. lactis to provide the observed protective effect.
To investigate the effect of direct intake of lactic acid on V. cholerae intestinal colonization, we performed oral gavage of lactic acid into V. cholerae-infected infant mice and observed a reduction of pathogen load similar to the treatment with L. lactis in 62.5% of the mice, whereas the rest of the litter showed a colonization akin to the mock-treated control ( fig. S7 ). These results indicate that although direct administration of lactic acid to the gastrointestinal tract can be sufficient to recapitulate the effect of L. lactis in the reduction of V. cholerae colonization, it is not as effective as the dietary intervention with live bacteria. Orally administered lactic acid is susceptible to neutralization during translocation from the stomach into the upper small intestine; in contrast, in situ production of lactic acid by transiting L. lactis cells allows a direct supply of acid that is independent of upstream gastrointestinal pH changes. Higher gastrointestinal pH increases the susceptibility to V. cholerae infection in humans, especially due to the use of acid-suppressing drugs such as proton pump inhibitors (17) . We evaluated the effect of the L. lactis intervention on V. cholerae-infected infant mice when oral gavage is performed using media buffered to pH 7.4 ( fig. S8 ). We found that under acid-neutralizing conditions, the survival of mock-treated mice was reduced to 11%, whereas the survival of L. lactis-treated mice was 50.8%, which suggests that probiotic intervention might ameliorate the impact of the disease even under conditions of increased susceptibility of infection.
Engineering cholera-sensing functions into L. lactis Next, we sought to engineer L. lactis to specifically detect and report on V. cholerae presence in the intestinal environment. V. cholerae produces the quorum-sensing molecules autoinducer-2 (AI-2) and cholera autoinducer 1 (CAI-1), and uses the two-component histidine kinase receptors LuxQ and CqsS to specifically detect each molecule, respectively (18) . Unlike AI-2, CAI-1 is unique to the genus Vibrio; therefore, we sought to develop a receptor in L. lactis to detect CAI-1 from V. cholerae. We took advantage of CqsS's specificity to CAI-1 and the modularity of histidine kinase receptors to design an L. lactis hybrid receptor (HR) that combines the transmembrane ligand binding domain of CqsS with the signal transduction domain of NisK, a two-component receptor in L. lactis that regulates the production of the lantibiotic nisin ( NisR-responsive nisA promoter and assayed each HR variant in a high-throughput coculture system with both wild-type V. cholerae and a V. cholerae cqsA deletion strain that is unable to produce CAI-1 (Fig. 3B) . The native nisRK two-component system and the majority of HR variants were not responsive to CAI-1 ( fig. S9, C and D) . However, a functional variant with a Glu-to-Gly mutation at residue 182 (HR4M) displayed robust repression of mCherry in the presence of CAI-1 (Fig. 3, C and D) . Detailed characterization of the dynamic response of HR4M to CAI-1 showed that mCherry repression occurred within 4 hours of L. lactis-V. cholerae coculture initiation, and the transcriptional response was entirely dependent on CAI-1 production by V. cholerae (Fig. 3E) . Nisin binding to NisRK is known to cause a conformational shift that activates autophosphorylation and induces transcription of the target gene (18) . However, the transcriptional repression observed suggested that HR4M preserves the phosphorelay properties of CqsS, wherein constitutive autophosphorylation is inhibited upon CAI-1 binding, leading to reduced transcription of target genes.
In situ detection of V. cholerae infection
We next incorporated a transcriptional inverter circuit that reprograms HR4M signaling into an activation response upon pathogen detection. As shown in Fig. 4A , we placed the gene encoding the transcriptional repressor TetR downstream of the HR4M-controlled nisA promoter to enable constitutive repression of an engineered Bacillus subtilis xylA-tetO promoter (21) in the absence of CAI-1.
Upon CAI-1 binding, HR4M repression of TetR expression enabled transcription from the xylA-tetO promoter ( fig. S10A) . We screened a library of tetR RBS sequences to identify an optimal TetR translation rate that would provide a suitable dynamic range of reporter gene expression upon CAI-1 induction (fig. S10B ). Detection circuit characterization in coculture conditions indicates that mCherry expression increased 60-fold in response to CAI-1 from V. cholerae with minimal signal background (Fig. 4B) . Although CAI-1-based quorum-sensing systems are present in most Vibrio spp., CAI-1 moieties might display different acyl chain lengths and modifications depending on the bacterial species (22) . We tested the specificity of HR4M to other CAI-1-producing and nonproducing bacterial species and found that the detection circuit did not respond to most of the environmental Vibrio strains tested or to non-CAI-1-producing bacteria ( fig. S11 ). However, Vibrio spp. producing CAI-1 moieties that are compatible with CqsS from V. cholerae such as Vibrio alginolyticus (22) were detected by HR4M ( fig. S11 ), suggesting that this system might be used for the detection of other pathogenic Vibrio spp. that produce CqsS-compatible quorumsensing molecules, such as Vibrio parahaemolyticus, Vibrio anguillarum, and Vibrio furnissii (22) .
As a proof of concept of a living diagnostic tool with an easy, point-of-need readout, we replaced mCherry with a secreted -lactamase reporter whose activity is readily visualized by a colorimetric shift from yellow to red after hydrolysis of the chromogenic substrate nitrocefin (23, 24) . Evaluation by in vitro coculture showed that the reporter strain, termed CSL, could generate a visible color change within 30 min when the coculture had reached a density of 10 8 CFU/ml of V. cholerae (Fig. 4C) . When the reporter assay was tested in the infant mouse model (Fig. 4D) , only the fecal pellets of mice dosed with a constitutive producer of -lactamase displayed a positive signal, demonstrating both the orthogonality and stability of the -lactamase reporter in the mouse intestinal environment (Fig. 4E) . Also, fecal pellets of mice dosed only with the L. lactis CSL strain did not display a color change, which demonstrates a tight regulation of the engineered detection circuit under in vivo conditions (Fig. 4E) . Finally, to determine whether L. lactis CSL could detect cholera infection in the infant mouse model, we administered two doses of the engineered strain, the first concurrent with V. cholerae and the second 10 hours after infection, to mice and collected stool samples for colorimetric assays (Fig. 4D) . The fecal samples of cholerainfected mice treated with L. lactis CSL showed positive signals after overnight incubation with nitrocefin, indicating circuit activation and -lactamase secretion in the gut (Fig. 4E) . In contrast, stool samples from uninfected mice and mice infected with the cqsA mutant of V. cholerae did not show colorimetric change, demonstrating that the circuit is CAI-1-specific.
Probiotic intervention with natural and engineered L. lactis
We found that, compared to wild-type L. lactis, the L. lactis CSL strain exhibited a reduced protective effect in our infant mouse model for cholera infection (Fig. 5A) . To understand this phenomenon, we studied the strain's growth and acidification dynamics in monoculture and coculture under anaerobic conditions (figs. S12 and S13). When assayed in the infant mouse model, the engineered L. lactis CSL strain had a lower median of recovered cells from the gut than the wild-type strain; however, no significant difference was detected between strains ( fig. S12A ). Under liquid culture conditions, L. lactis CSL acidifies medium slower than the wild-type strain ( fig. S12B) . Furthermore, the viability of the L. lactis CSL strain decreases under extended coculture condition, and the steady-state pH is higher than the coculture with wild-type L. lactis ( fig. S12B) . Also, given the observed defect in acidification, the V. cholerae killing by L. lactis CSL is delayed by 4 hours compared to wild-type L. lactis ( fig. S12C) . The results we obtained indicate that circuit activation and -lactamase secretion in the engineered L. lactis strain create a metabolic burden that reduces the bacteria's natural acidification capacities and its antagonistic effect on V. cholerae, further supporting the hypothesis that lactic acid production in the gut environment plays a key role in the protective effect. To achieve a combined protective and diagnostic function, we introduced a mixed population of wild-type and CSL L. lactis into the feeding regimen (Fig. 5A) . The combined dose of natural and engineered L. lactis successfully restored the protective effect and provided an effective diagnostic readout in stools (Fig. 5, A and B) .
DISCUSSION
Here, we present evidence indicating that the common lactic acid bacterium L. lactis, through its natural acidification function, can be used to inhibit V. cholerae infection in a mouse model. Our experiments demonstrate that dietary interventions with metabolically active probiotic bacteria can be used as an effective strategy to induce modifications of the intestinal microenvironment that in turn lead to the enhancement of colonization resistance against a major intestinal pathogen. The infection model used in this work allows infant mice to feed ad libitum from the mother, a situation that provides them with a constant source of lactose, favoring the L. lactis-mediated production of lactic acid in the intestinal environment. The beneficial effects of ingesting metabolically active L. lactis have been observed in other animal models of cholera infection-Zamri et al. (25) noted that oral vaccination of adult rabbits with wild-type and recombinant L. lactis expressing V. cholerae membrane proteins abolished the diarrheal symptoms of the cholera infection. Although antimicrobial properties of lactic acid have been widely applied as a food preservation method (26), our findings uncover that regular ingestion of metabolically active L. lactis represents an effective means to deliver lactic acid to the intestinal environment and create inhospitable conditions for V. cholerae proliferation. Future implementation of probiotic interventions with L. lactis in humans will require a formulation system that ensures the delivery of sufficient quantities of probiotic bacteria and key metabolic substrates so that lactic acid production occurs regardless of the individual's diet or intestinal conditions. The use of microbiotamodulating interventions represents an emerging strategy that might confer rapid protection against fast-developing infections like cholera. Notably, Hubbard et al. (27) created a live cholera vaccine candidate that provides colonization resistance in a probioticlike fashion, conferring cholera protection within 1 day in an infant rabbit model.
Here, we have also demonstrated the rational design and development of a synthetic gene circuit that enables L. lactis to detect and respond to V. cholerae both in vitro and in the intestinal environment. We further coupled the circuit to a proof-of-concept enzyme-based assay that reports the in situ detection of the pathogen through a simple colorimetric assay on stools, demonstrating the potential of engineered probiotics as point-of-need diagnostic tools. Our results indicate that in situ biosensing and reporting of the pathogen presence is feasible through the use of synthetic gene networks and stable, orthogonal reporter enzymes that can survive the intestinal environment. Future application of such living diagnostics in the field will entail optimization of the response time to readable output to obtain diagnostic results within clinically relevant time scales. Furthermore, there are additional technological and regulatory limitations that need to be addressed before in vivo diagnostic systems are suitable for deployment in cholera endemic areas. The -lactamase-based enzymatic reporter used here as signal output is suitable for laboratory experiments; however, its use in the field is restricted due to potential horizontal gene transfer of the -lactamase gene to pathogenic bacteria and cost-effectiveness of the use of its substrate, nitrocefin. Therefore, there is a need for the development of a food-grade enzymatic reporter that is orthogonal to the human intestine and whose cognate substrate can be produced cost-effectively and distributed en masse in low-resource settings.
Our work sets the stage for dietary interventions with natural and engineered probiotics as an alternative strategy to combat the spread of cholera in vulnerable populations. Household contact with infected individuals is among the highest known risk factors for subsequent infection and dehydration (28) . Regular consumption of affordable, home-fermented food products containing live L. lactis may not only diminish the severity of the disease through colonization resistance, but if used in combination with a living diagnostic L. lactis strain, it may also provide an opportune alert for patients to seek further medical intervention and a timely warning for close contacts to apply sanitary measures to prevent transmission. The use of biologics-based prophylaxis, such as the probiotic intervention presented in this study or the recently proposed phagebased prophylaxis (29) , could serve as an alternative to conventional chemoprophylaxis, limiting the emergence of antibiotic resistance in the population (28) . The implementation of engineered probiotics, such as the L. lactis CSL strain, has the potential to provide community-level surveillance of cholera cases and could help to elucidate the contribution of asymptomatic carriage of V. cholerae to disease transmission (30) . The development of living diagnostic bacteria (31) (32) (33) (34) (35) represents a promising approach to achieve near real-time surveillance of multiple pathological conditions. Our work advances this endeavor by demonstrating the design and construction of a hybrid sensing and reporting system, which provides a molecular architecture strategy for generalizable "sense-and-respond" bioengineering, expanding the possible targets of detection and the variety of engineerable sensor bacteria.
MATERIALS AND METHODS

Study design
The overall objective of this work was to demonstrate that microbiotamodulating interventions with natural and engineered probiotics might represent a plausible strategy to achieve two high-priority goals in the fight against cholera, namely, enhancement of colonization resistance and point-of-need diagnostics for disease surveillance. We hypothesized that the transient colocalization of ingested L. lactis and V. cholerae could be leveraged to promote colonization resistance through the in situ production of lactic acid and to detect the presence of the pathogen at an early stage of the infection. We used a synthetic biology approach to construct a hybrid-signaling pathway in L. lactis that enables the detection of quorum-sensing signals that are indicative of V. cholerae infection. After in vitro validation of these hypotheses, we used the infant mouse model of cholera infection to evaluate the efficacy of the proposed dietary intervention using survival, intestinal colonization, and production of diagnostic enzymatic reporters as the principal outcomes. To optimize the number of mice needed in each trial without compromising the power of the study, we performed the survival studies in a randomized cross-litter manner (except for the three whole-litter studies in fig. S5 ). Each trial was performed with at least three litters. Each litter was randomly divided into two to three groups with a random number generator. Each group was assigned to a different treatment. Overall, each treatment covered individual mice from at least three litters, and data were collected over two or more independent trials [apart from the heat-inactivated (Fig. 2F ) and ldhcomplemented (Fig. 2E) L. lactis tests, each from one independent trial]. No blinding was performed in either experiments or data analysis. Sample sizes were determined by power analysis to reach a statistical power of 0.8 or higher using the pwr package in R.
All mice in this study were treated in accordance with protocol number IS00000852, approved by Harvard Medical School Institutional Animal Care and Use Committee and the Committee on Microbiological Safety. Primary data are reported in table S1. A detailed description of all experimental procedures performed in this study is included in the Supplementary Materials and Methods.
Statistical analysis
Statistics were performed with GraphPad Prism 5.0c. Log-rank tests were performed for all survival studies, assuming the mice in each group were independent and the hazard ratio was consistent over the study period. Each treatment group was predefined randomly cross litters at the beginning of the study (details in the Supplementary Materials and Methods). Mann-Whitney test was used where each data point was independent from each other, and no Gaussian distribution was assumed. P values reported in the figure legends are two-tailed. Specific sample size, P value, and other details for each test are described in the figure legends.
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